Baseline characteristics according to cytoreductive treatment
| Characteristics . | IFN-α2 (N = 53) . | IFN-α2 + Statin (N = 30) . | HU (N = 23) . | HU + Statin (N = 23) . | P value . |
|---|---|---|---|---|---|
| Age, y | 57.3 (51.2-64.6) | 60.3 (54.9-69.2) | 70.3 (65.9-78.6) | 74.1 (69.6-77.3) | <.001 |
| Sex, male | 31 (58.5) | 20 (66.7) | 5 (21.7) | 8 (34.8) | .002 |
| MPN subtype | |||||
| ET | 15 (28.3) | 12 (40) | 8 (34.8) | 8 (34.8) | .617 |
| PV | 30 (56.6) | 13 (43.3) | 13 (56.5) | 12 (52.2) | |
| Prefibrotic myelofibrosis | 3 (5.7) | 2 (6.7) | 2 (8.7) | 3 (13) | |
| Primary myelofibrosis | 5 (9.4) | 3 (10) | 0 | 0 | |
| Driver mutation | |||||
| JAK2V617F | 39 (73.6) | 24 (80) | 18 (78.3) | 20 (87) | .603 |
| CALR | 11 (20.8) | 4 (13.3) | 2 (8.7) | 1 (4.4) | |
| MPL | 2 (3.8) | 0 | 1 (4.4) | 1 (4.4) | |
| Triple negative | 1 (1.9) | 2 (6.7) | 2 (8.7) | 1 (4.4) | |
| Follow-up time, years | 4.8 (2.3-6.5) | 5.6 (2.8-7.1) | 4.5 (1.6-6.5) | 3.9 (1.7-5.6) | .514 |
| Smoking status | |||||
| Never | 37 (69.8) | 16 (53.3) | 12 (52.2) | 8 (34.8) | .054 |
| Former | 10 (18.9) | 9 (30) | 5 (21.7) | 12 (52.2) | |
| Current | 6 (11.3) | 5 (16.7) | 6 (26.1) | 3 (13) | |
| Alcohol, units per week | |||||
| ≤10 | 23 (43.4) | 11 (36.7) | 11 (47.8) | 12 (52.2) | .650 |
| >10 | 9 (17) | 6 (20) | 2 (8.7) | 3 (13) | |
| Missing | 21 (39.6) | 13 (56.5) | 10 (43.5) | 8 (34.8) | |
| BMI, kg/m2 | 25.2 (22.6-27.7) | 25.9 (23.7-28.8) | 23.8 (22.5-27.4) | 23.9 (22.1-27) | .354 |
| Comorbidities | |||||
| Hypertension∗ | 13 (24.5) | 20 (66.7) | 12 (52.2) | 18 (78.3) | <.001 |
| Type 2 diabetes | 3 (5.7) | 8 (26.7) | 0 | 2 (8.7) | .006 |
| Thromboembolic event† | 15 (28.3) | 13 (43.3) | 4 (17.4) | 14 (60.9) | .008 |
| Statin treatment | .285 | ||||
| Moderate intensity‡ | 18 (60) | 15 (65.2) | |||
| High intensity§ | 12 (40) | 8 (34.8) | |||
| Laboratory test | |||||
| Hemoglobin, g/dL | 16.6 (13.9-18.2) | 15.5 (13.5-18.4) | 15.5 (14.2-19.2) | 15.3 (14-16.8) | .628 |
| Erythrocytes, ×1012/L | 5.6 (4.7-6.6) | 5.1 (4.7-6.1) | 5.6 (5.0-7.2) | 5.3 (4.6-6.0) | .284 |
| WBC, ×109/L | 9.3 (7.1-11.8) | 10.3 (8.3-13.0) | 10.1 (8.5-14.3) | 9.7 (8.3-11.6) | .605 |
| Platelets, ×109/L | 634 (478-862) | 594 (523-750) | 715 (429-916) | 603 (506-736) | .768 |
| JAK2V617F, % | 35.2 (13.3-48) | 36.6 (20.5-50) | 31.8 (13-44.3) | 31.2 (16.8-40) | .922 |
| Total cholesterol, mmol/L | 4.6 (4.2-5.3) | 3.8 (3.2-4.3) | 5.4 (4.7-5.9) | 4.1 (3.5-4.6) | <.001 |
| LDL-C, mmol/L | 2.7 (2.1-3.3) | 1.7 (1.5-2.3) | 3.0 (2.8-3.3) | 1.9 (1.7-2.1) | <.001 |
| Characteristics . | IFN-α2 (N = 53) . | IFN-α2 + Statin (N = 30) . | HU (N = 23) . | HU + Statin (N = 23) . | P value . |
|---|---|---|---|---|---|
| Age, y | 57.3 (51.2-64.6) | 60.3 (54.9-69.2) | 70.3 (65.9-78.6) | 74.1 (69.6-77.3) | <.001 |
| Sex, male | 31 (58.5) | 20 (66.7) | 5 (21.7) | 8 (34.8) | .002 |
| MPN subtype | |||||
| ET | 15 (28.3) | 12 (40) | 8 (34.8) | 8 (34.8) | .617 |
| PV | 30 (56.6) | 13 (43.3) | 13 (56.5) | 12 (52.2) | |
| Prefibrotic myelofibrosis | 3 (5.7) | 2 (6.7) | 2 (8.7) | 3 (13) | |
| Primary myelofibrosis | 5 (9.4) | 3 (10) | 0 | 0 | |
| Driver mutation | |||||
| JAK2V617F | 39 (73.6) | 24 (80) | 18 (78.3) | 20 (87) | .603 |
| CALR | 11 (20.8) | 4 (13.3) | 2 (8.7) | 1 (4.4) | |
| MPL | 2 (3.8) | 0 | 1 (4.4) | 1 (4.4) | |
| Triple negative | 1 (1.9) | 2 (6.7) | 2 (8.7) | 1 (4.4) | |
| Follow-up time, years | 4.8 (2.3-6.5) | 5.6 (2.8-7.1) | 4.5 (1.6-6.5) | 3.9 (1.7-5.6) | .514 |
| Smoking status | |||||
| Never | 37 (69.8) | 16 (53.3) | 12 (52.2) | 8 (34.8) | .054 |
| Former | 10 (18.9) | 9 (30) | 5 (21.7) | 12 (52.2) | |
| Current | 6 (11.3) | 5 (16.7) | 6 (26.1) | 3 (13) | |
| Alcohol, units per week | |||||
| ≤10 | 23 (43.4) | 11 (36.7) | 11 (47.8) | 12 (52.2) | .650 |
| >10 | 9 (17) | 6 (20) | 2 (8.7) | 3 (13) | |
| Missing | 21 (39.6) | 13 (56.5) | 10 (43.5) | 8 (34.8) | |
| BMI, kg/m2 | 25.2 (22.6-27.7) | 25.9 (23.7-28.8) | 23.8 (22.5-27.4) | 23.9 (22.1-27) | .354 |
| Comorbidities | |||||
| Hypertension∗ | 13 (24.5) | 20 (66.7) | 12 (52.2) | 18 (78.3) | <.001 |
| Type 2 diabetes | 3 (5.7) | 8 (26.7) | 0 | 2 (8.7) | .006 |
| Thromboembolic event† | 15 (28.3) | 13 (43.3) | 4 (17.4) | 14 (60.9) | .008 |
| Statin treatment | .285 | ||||
| Moderate intensity‡ | 18 (60) | 15 (65.2) | |||
| High intensity§ | 12 (40) | 8 (34.8) | |||
| Laboratory test | |||||
| Hemoglobin, g/dL | 16.6 (13.9-18.2) | 15.5 (13.5-18.4) | 15.5 (14.2-19.2) | 15.3 (14-16.8) | .628 |
| Erythrocytes, ×1012/L | 5.6 (4.7-6.6) | 5.1 (4.7-6.1) | 5.6 (5.0-7.2) | 5.3 (4.6-6.0) | .284 |
| WBC, ×109/L | 9.3 (7.1-11.8) | 10.3 (8.3-13.0) | 10.1 (8.5-14.3) | 9.7 (8.3-11.6) | .605 |
| Platelets, ×109/L | 634 (478-862) | 594 (523-750) | 715 (429-916) | 603 (506-736) | .768 |
| JAK2V617F, % | 35.2 (13.3-48) | 36.6 (20.5-50) | 31.8 (13-44.3) | 31.2 (16.8-40) | .922 |
| Total cholesterol, mmol/L | 4.6 (4.2-5.3) | 3.8 (3.2-4.3) | 5.4 (4.7-5.9) | 4.1 (3.5-4.6) | <.001 |
| LDL-C, mmol/L | 2.7 (2.1-3.3) | 1.7 (1.5-2.3) | 3.0 (2.8-3.3) | 1.9 (1.7-2.1) | <.001 |
Data are presented as n (%) or median (IQR).
BMI, body mass index; WBC, white blood cell.
Defined by usage of antihypertensive drugs.
Thromboembolic events prior to diagnosis recorded; Cerebral infarct, acute myocardial infarct (STEMI and NSTEMI), deep venous thrombosis, pulmonary embolism, transient ischemic attack and amaurosis fugax.
Includes atorvastatin 10-20 mg, simvastatin 20-40 mg and rosuvastatin 5-10 mg.
Includes atorvastatin 40-80 mg.